Healthcare Journalists are Suffering
The pandemic has pushed healthcare to the brink. Healthcare journalists struggle to make sense of it, finding themselves isolated, trapped...
When Ease-of-use is the Endpoint
Healthcare struggles with thinking fast. We like snap decisions when treating diseases. But in the process, we have forgotten that...
Care Gaps Predict Telemedicine Trends
We like to predict the future of telemedicine. But these predictions are often speculative. The most likely trends in telemedicine...
Why Decision Makers Make Wrong Decisions
In recent weeks, the CDC has struggled with policy reversals and communication errors. Yet its leaders continue to project confidence...
Healthcare Dies in the Supreme Court
The Supreme Court ruled against vaccine mandates for large employers. It was an expected ruling that fell along partisan lines....
When Health Media Becomes Healthcare
Media outlets have become the primary source of healthcare information, replacing traditional clinical journals. But the difference between the two...
How to Introduce the Fourth Booster
It is only a matter of time before we hear of the fourth COVID booster. The timing will correspond with...
We Have More, but Fewer COVID-19 Treatments
The FDA has authorized multiple COVID treatments, but they remain limited for the foreseeable future due to the belief that...
Is Climate Change a Healthcare Issue?
Climate change is a healthcare issue. But it affects healthcare at large more than it does individual patients. Therefore, we...
Normalizing Healthcare Policy Polarizations
Public health is a field that thrives on compromise. Yet we have polarized and distorted it into something different. By...
The Start of Decentralized Healthcare
The push to decentralize healthcare will be defined by a shift in power from hospitals to payer networks. The shift...
Risk Mitigating with Healthcare Venture Capital
Healthcare venture capital has enjoyed unprecedented growth. A trend that will continue as healthcare embraces new reimbursement models - because...
BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us
Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...
Read more